Shares of the biotech company RBT (BioTechnologies Development) have become available for trading on the Moscow Exchange over-the-counter (OTC) market of shares. Trading symbol: RBTY
According to Igor Krasilnikov, director of RBT, "In June 2023, Artgen Biotech, our venture investor and organizer of the private placement of RBT JSC, recommended that RBT management create opportunities for its shareholders for liquidity and circulation of shares on the secondary market. This is an extraordinary task, but thanks to the new OTC segment of the Moscow Exchange, we were able to implement these plans already in 2023."
The infrastructure created on the basis of the Moscow Exchange for concluding over-the-counter transactions in shares without listing with settlements through a central counterparty (CCP) provides opportunities for investors to buy or sell shares of non-public companies before they go public and, thereby, increase their potential profits.
According to the Moscow Exchange, from December 22, the total number of unlisted securities available for transactions will reach 28 shares. In the future, it is planned to expand the list of available tools.
Detailed information about over-the-counter stock transactions and a list of brokerage companies providing access to the service are posted on the Moscow Exchange website.
The service for concluding over-the-counter transactions in shares with settlements through a CCP has become available since April 2023. Users have access to over-the-counter transactions with shares of Russian companies without listing, as well as with shares listed on the Moscow Exchange. Since the start of work, the total volume of operations has exceeded RUB 54 bln. The purchase and sale of securities is available to qualified investors; non-qualified investors can sell securities. No additional connection of professional trading participants to the over-the-counter stock market with a CCP is required.
RBT is a company of the Artgen Biotech group (ex. HSCI, MOEX: ABIO), resident of Skolkovo and Medtech Technopark. With the support of industrial partner Artgen Biotech and its ecosystem, RBT is elaborating a platform for the development of antiviral vaccines based on surface recombinant proteins and spherical adjuvant particles. Previously, this platform was used to develop vaccines against coronavirus Betuvax-Kov-2 and influenza - TetraFluBET, as well as a combined pentavalent vaccine against influenza and coronavirus, developed jointly with pharmaceutical holding Nacimbio. RBT's technological platform is aimed at making vaccines less reactogenic and with a minimum of side effects. At the same time, the "protective" properties of vaccines, such as immunogenicity, remain at a high level. The company's portfolio also includes a vaccine against human papilloma virus.
In July 2023, RBT raised RUB 155 mln during a private placement on the Rounds investment platform. Investments will be used to expand the company's development portfolio.